Results 91 to 100 of about 38,476 (212)
PLoS ONE, 2012 BackgroundDabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal. Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost ...
Joyce H S You +3 more
doaj +1 more source
Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]
, 2017 A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Albaladejo Martínez, Alberto +2 more
core +2 more sources
Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 46-62, January 2026.Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik +7 more
wiley +1 more source
Vascular Health and Risk Management, 2013 Andreas Clemens,1 Mandy Fraessdorf,2 Jeffrey Friedman31Corporate Division Medicine, TA Cardiovascular, 2Medical Data Services, Boehringer Ingelheim GmbH & Co KG, Ingelheim am Rhein, Germany; 3Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT ...
Clemens A, Fraessdorf M, Friedman J
doaj
Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.ABSTRACT A physiologically‐based pharmacokinetic (PBPK) model of niraparib and its primary metabolite using a relevant virtual cancer population is reported here. A series of in vitro experiments using liver S9, microsomes, and hepatocytes with various inhibitors and recombinant supersomes demonstrated that niraparib is specifically metabolized by ...
Gareth J. Lewis +3 more
wiley +1 more source
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Health and Quality of Life Outcomes, 2017 Background Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource ...
Shannon L. Reynolds +9 more
doaj +1 more source
Annals of Noninvasive Electrocardiology, Volume 31, Issue 1, January 2026.To compare the acute and long‐term outcomes of high‐power ablation for typical atrial flutter using a 4‐mm irrigated catheter (4‐IC) versus an 8‐mm non‐irrigated catheter (8‐NIC). We conducted a retrospective cohort study of 215 patients who underwent cavotricuspid isthmus (CTI) ablation between January 2019 and December 2024.
Hina Pervaiz +5 more
wiley +1 more source
Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
Pharmaceuticals, 2012 Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients.
Josef Finsterer, Claudia Stöllberger
doaj +1 more source
Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation:Contemporary findings in real-life Danish patients [PDF]
, 2017 Background The nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on real‐life patient experience, including bleeding ...
Evans, David +8 more
core +3 more sources
Dabigatran Treatment Increased Closure Device-Related Thrombosis by Platelet Activation in Patients Undergoing Percutaneous Left Atrial Appendage Closure [PDF]
, 2021 Xiaoye Li +6 more
openalex +1 more source